Who Optimizes SG&A Costs Better? Ascendis Pharma A/S or Perrigo Company plc

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Ascendis Pharma A/S and Perrigo Company plc, two industry players, showcase contrasting strategies over the past decade.

Ascendis Pharma A/S: A Steady Climb

From 2014 to 2023, Ascendis Pharma A/S has seen a significant increase in SG&A expenses, rising from approximately $6.3 million to $264 million. This represents a staggering 4,100% increase, reflecting their aggressive expansion and investment in growth.

Perrigo Company plc: Consistent Management

In contrast, Perrigo Company plc maintained a more stable SG&A expense profile, with figures hovering around $1.1 billion to $1.3 billion annually. This stability suggests a focus on efficiency and cost control, crucial for sustaining profitability in a volatile market.

Conclusion

While Ascendis Pharma A/S is investing heavily in its future, Perrigo Company plc's consistent cost management highlights its strategic focus on operational efficiency.